Clinical Trials in San Antonio

Showing 1721-1740 of 7,028 trials

rTMS for Stimulant Use Disorders

NCT04907357

The purpose of the study is to determine feasibility of repetitive transcranial magnetic stimulation (rTMS) for individuals with moderate to severe cocaine or methamphetamine use disorder (CUD/MUD). Potential participants will be age 18-65, and interested in cutting down or stopping use. Participants will be randomized to one of two groups; groups will receive rTMS or sham rTMS (placebo) over the course of an 8-week treatment period, and complete follow-up assessments at the end of treatment, 12, and 16 weeks post-randomization.

Cocaine Use DisorderMethamphetamine AbuseCocaine Dependence+6 more

Medical University of South Carolina129 participantsStarted Feb 2022

Winston-Salem, North Carolina, United States • Charleston, South Carolina, United States • Dallas, Texas, United States +1 more locations

COMPLETEDPhase 2< 1 mile

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

NCT04963231

The purpose of this study was to evaluate the safety and efficacy of once daily subcutaneous (SC) administration of setmelanotide in participants with obesity and specific gene variants in the MC4R pathway.

Genetic Obesity

Rhythm Pharmaceuticals, Inc.164 participantsStarted Nov 2021

Scottsdale, Arizona, United States • Suwanee, Georgia, United States • Worcester, Massachusetts, United States +33 more locations

rTMS for Stimulant Use Disorders

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

Find Trials by Condition in San Antonio

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

SGLTi, Hepatic Glucose Production and Ketogenesis

A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

Vaginal Ecosystem and Network in the United States Study

STEM-PD Open Label Extension (OLE)

Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT)

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma